Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-25
2007-09-25
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
11116319
ABSTRACT:
The proapoA-I mutants of the present invention exhibit superior LDL-antioxidant activities over the wild-type proapoA-I and higher efficiencies for delivering cholesterol to hepatocytes than the previously reported apoA-I-R173C, and thus they can be effectively used for prevention and treatment of hyperlipidemia or atherosclerosis.
REFERENCES:
patent: 5059528 (1991-10-01), Bollen et al.
patent: 5643757 (1997-07-01), Malik et al.
patent: 5876968 (1999-03-01), Sirtori et al.
patent: 5990081 (1999-11-01), Ageland et al.
patent: 6897039 (2005-05-01), Graversen et al.
patent: WO90/12879 (1990-11-01), None
patent: WO94/13819 (1994-06-01), None
patent: WO96/37608 (1996-11-01), None
Jerzy-Roch Nofer et al., “HDL and Arteriosclerosis: beyond reverse cholesterol transport,” Atherosclerosis 161 (2002), pp. 1-16.
Jere P. Segrest et al., “Structure and function of apolipoprotein A-1 and high-density lipoprotein,” Current Opinion in Lipidology, (2000), pp. 105-115.
Olga Stein, et al., “Atheroprotective mechanism of HDL,” Atherosclerosis 144 (1999), pp. 285-301.
David K. Spady, “Reverse Cholesterol Transport and Atherosclerosis Regression,” Circulation 100, (Aug. 10, 1999), pp. 576-578.
George H. Rothblat et al., “Cell cholesterol efflux: integration of old and new observations provides new insights,” Journal of Lipid Research, vol. 40, (1999), pp. 781-796.
J. Koizumi, et al., “Behavior of human apolipoprotein A-I: phospholipid and apolHDL:phospholipid complexes in vitro and after injection into rabbits,” Journal of Lipid Research, vol. 29, (1988), pp. 1405-1415.
David J. Gordon and Basil M. Rifkind, “High-density lipoprotein—the clinical implications of recent studies,” The New England Journal of Medicine 321, (Nov. 9, 1989), pp. 1311-1316.
Giulia Chiesa and Cesare R. Sirtori, “Recombinant apolipoprotein A-IMilano: a novel agent for the induction of regression of atherosclerotic plaques,” Annuals of Medicine 35, (2003), pp. 267-273.
Marian C. Cheung et al., “Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease,” Journal of Lipid Research, vol. 32, (1991), pp. 383-394.
J.C. Fruchart and G. Ailhaud, Apolipoprotein A-Containing Lipoprotein Particles: Physiological Role, Quantification, and Clinical Significance,: Clinical Chemistry, vol. 38, No. 6, (1992), pp. 793-797.
Edward M. Rubin, et al., “Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI,” Nature, vol. 353, (Sep. 19, 1991), pp. 265-267.
Chris Paszty et al., “Apolipoprotein AI Transgene Corrects Apolipoproten E Defeciency-induced Atherosclerosis in Mice,” J. Clin. Invest., vol. 94, (Aug. 1994), pp. 899-903.
Alexander C. Liu, et al., “Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice,” Journal of Lipid Research, Vo. 35, (1994), pp. 2263-2267.
Prediman K. Shah, et al., “Effects of Recombinant Apolipoprotein A-1Milanoon Aortic Atherosclerosis in Apolipoprotein E-Deficient Mice,” Circulation 97 (1998) pp. 780-785.
Prediman K. Shah et al., “High Dose Recombinant Apolipoprotein A-1MilanoMobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice,” Circulation 103, (2001), pp. 3047-3050.
Andrew G. Lacko and Norman E. Miller, “International Symposium on the Role of HDL in Disease Prevention: Report on a Meeting,” Journal of Lipid Research, vol. 38 (1997), pp. 1267-1273.
Steven E. Nissen et al., “Effect of Recombinant ApoA-1 Milano on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes,” JAMA 290, No. 17, (Nov 5, 2003), pp. 2292-2300.
Steven E. Nissen et al., “Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis,” JAMA 291, No. 9, (Mar. 3, 2004), pp. 1071-1080.
Kyung-Hyun Cho and Ana Jonas, “A Key Point Mutation (V156E)Affects the Structure and Functions of Human Apolipoprotein A-I,” The Journal of Biological Chemistry, vol. 275, No. 35, (Sep. 1, 2000), pp. 26821-26827.
Charles E. Matz and Ana Jonas, Micellar Complexes of Human Apolipoprotein A-1 with Phosphatidylcholines and Cholesterol Prepared from Cholate-Lipid Dispersions, The Journal of Biological Chemistry, vol. 257, No. 8, (Apr. 25, 1982), pp. 4535-4538.
James V. Staros, “N-Hydroxysulfosuccinimide Active Esters: Bis (N-hydroxysulfosuccinimide) Esters of Two Dicarboxylic Acids Are Hydrophilic, Membrane-Impermeant, Protein Cross-Linkers,” Biochemistry, vol. 21, No. 17, (1982), pp. 3950-3955.
Zhen Jia et al., “Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoprotein A-IMilano,” Biochemical and Biophysical Research Communications 297, (2002), pp. 206-213.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Monshipouri Maryam
LandOfFree
ProapolipoproteinA-I mutant and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ProapolipoproteinA-I mutant and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ProapolipoproteinA-I mutant and pharmaceutical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788330